Treating patients with metastatic renal carcinoma: an escape from Phase III.
about
Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting.Sequential therapy in metastatic clear cell renal carcinoma: TKI-TKI vs TKI-mTOR.Feasibility, efficacy and safety of tyrosine kinase inhibitor treatment in hemodialyzed patients with renal cell cancer: 10 years of experience.
P2860
Treating patients with metastatic renal carcinoma: an escape from Phase III.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Treating patients with metastatic renal carcinoma: an escape from Phase III.
@en
type
label
Treating patients with metastatic renal carcinoma: an escape from Phase III.
@en
prefLabel
Treating patients with metastatic renal carcinoma: an escape from Phase III.
@en
P2860
P356
P1476
Treating patients with metastatic renal carcinoma: an escape from Phase III
@en
P2093
Fable Zustovich
Patrizia Farina
P2860
P304
P356
10.1586/ERA.12.64
P577
2012-07-01T00:00:00Z